FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial. PMID 40975112 · Lancet · 2025-Oct-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial. PMID 41046179 · Eur Urol · 2025-Oct-03 The record describes a randomized trial in oncology with a drug intervention and time-to-event endpoints, but the trial phase (Phase III/IIIb or Phase II/III) is not explicitly established in the provided abstract or metadata, which is required for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of bupivacaine liposome transversus abdominis plane block in enhancing postoperative recovery following laparoscopic colorectal cancer resection. PMID 41042339 · Langenbecks Arch Surg · 2025-Oct-03 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlers. PMID 40966979 · Vaccine · 2025-Oct-03 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Corrigendum to "A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve Japanese adults ≥65 years of age" [Vaccine 62 (2025) 127456]. PMID 40916264 · Vaccine · 2025-Oct-03 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Targeted Blockade of Terminal C5a Is Critical to Management of Sepsis and Acute Respiratory Distress Syndrome: The Mechanism of Action of Vilobelimab. PMID 41096893 · Int J Mol Sci · 2025-Oct-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The effectiveness of adding Braun anastomosis to standard Child reconstruction to reduce delayed gastric emptying after pancreatoduodenectomy (REMBRANDT): study protocol for a multicentre randomised-controlled trial. PMID 41039614 · Trials · 2025-Oct-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Paleolithic diet fraction and score in post hoc data analysis of a randomized controlled trial with lifestyle interventions for abdominal obesity. PMID 41039470 · BMC Nutr · 2025-Oct-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy. PMID 41038856 · NPJ Breast Cancer · 2025-Oct-02 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 3 Figure · 6 Panel · risk not_visible |
| Evaluation of a Translatable Web-Based Intervention for Increasing Physical Activity Among Cancer Survivors: Pilot Randomized Trial. PMID 41037739 · JMIR Cancer · 2025-Oct-02 The study is a pilot randomized trial of a web-based physical activity intervention for cancer survivors. It is oncology-related and human, but it lacks a drug intervention and a time-to-event efficacy endpoint. The phase is not specified as definitive (III/IIIb or II/III), and the primary outcome is feasibility/physical activity, not survival or time-to-event. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clesrovimab for Prevention of RSV Disease in Healthy Infants. PMID 40961446 · N Engl J Med · 2025-Oct-02 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. PMID 40888739 · N Engl J Med · 2025-Oct-02 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers. PMID 40865526 · Cell · 2025-Oct-02 The record describes a biomarker/transcriptomic analysis performed on archived samples from patients enrolled in Phase 3 trials. It is not the original report of those trials' primary efficacy results. Therefore, while it meets many criteria (oncology, human, randomized, phase 3, drug intervention, time-to-event endpoint), it fails the 'original_result' criterion as it is a secondary analysis, not the definitive trial report. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prenatal Intravenous Iron and Child Growth: A Secondary Analysis of a Randomized Clinical Trial. PMID 41148141 · JAMA Netw Open · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study. PMID 41124598 · Oncologist · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Trial Enrollment and Survival Disparities Among Patients With Advanced Epithelial Ovarian Carcinoma. PMID 41123892 · JAMA Netw Open · 2025-Oct-01 This is a secondary, retrospective cohort analysis evaluating racial disparities across multiple historical GOG RCTs. It is not a primary report of a Phase III/IIIb or Phase II/III randomized trial with a drug intervention as the key element. The phase of the underlying trials is not explicitly stated in the provided metadata, and the report does not focus on a specific drug intervention, making it ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preserved Cognitive Function After Statin Administration During Cancer Treatment With Doxorubicin: A Secondary Analysis of a Randomized Clinical Trial. PMID 41118164 · JAMA Netw Open · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Clinical Significance of a Multicancer Screening Trial With Stage-Based End Points. PMID 41066125 · JAMA Netw Open · 2025-Oct-01 The study is an independent decision-analytic model estimating outcomes of a planned screening trial, not a clinical trial report. It does not involve a drug intervention, and its outcomes (late-stage incidence reductions, mortality reductions over fixed periods) are not time-to-event endpoints in the required sense. The trial phase is not specified. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life assessment in trials testing tyrosine kinase inhibitors or immune checkpoints inhibitors in early-stage NSCLC. PMID 41056430 · Oncologist · 2025-Oct-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Adjunctive brexpiprazole in patients with major depressive disorder who show minimal or partial response to antidepressant treatment: post hoc analysis of randomized controlled trials. PMID 41055581 · Int J Neuropsychopharmacol · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials. PMID 41034823 · BMC Cancer · 2025-Oct-01 The study meets most criteria but fails the critical time-to-event endpoint requirement. The primary efficacy outcome is the proportion of patients without nausea in the overall phase (0-120h), which is a categorical response rate, not a time-to-event measure like OS, PFS, or similar. No Kaplan-Meier curves or hazard ratios are mentioned. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Privacy-by-Design Approach to Generate Two Virtual Clinical Trials for Multiple Sclerosis and Release Them as Open Datasets: Evaluation Study. PMID 41032725 · J Med Internet Res · 2025-Oct-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer: A Randomized Clinical Trial. PMID 41032300 · JAMA Netw Open · 2025-Oct-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 3 Panel · risk unclear |
| Phase II trial of radiotherapy plus Huachansu in elderly or chemotherapy-ineligible patients with locally advanced esophageal squamous cell carcinoma. PMID 41021440 · Oncologist · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A prospective study of serum folate levels in patients with solid tumors treated with olaparib. PMID 41014151 · Oncologist · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT. PMID 40986647 · Cancer · 2025-Oct-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Effect of a whole food plant-based dietary intervention on cancer progression and inflammatory markers. PMID 40973844 · Oncologist · 2025-Oct-01 The study is a randomized trial in metastatic breast cancer reporting original results, but it lacks a primary/key secondary time-to-event efficacy endpoint (only biomarker changes are reported), the intervention is dietary (not a drug), and it does not explicitly establish a Phase III/IIIb or Phase II/III status. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma. PMID 40973474 · Oncologist · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Toxicity-benefit analysis of advanced prostate cancer trials using weighted toxicity scoring. PMID 40973467 · Oncologist · 2025-Oct-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Total tumor volume predicts overall survival and response to induction chemotherapy in patients with colorectal cancer liver metastases: An ancillary study of the phase 3 CAIRO5 trial. PMID 40912057 · Eur J Cancer · 2025-Oct-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Dexmedetomidine for Analgesia in Nonintubated Patients With Traumatic Rib Fractures: A Randomized Clinical Trial. PMID 40900569 · JAMA Surg · 2025-Oct-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of 177Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol. PMID 40876952 · J Nucl Med · 2025-Oct-01 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI). PMID 40876084 · Eur J Cancer · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Prognostic Subgroups for Disease-Free Survival With Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Secondary Analysis of a Randomized Clinical Trial. PMID 40875250 · JAMA Otolaryngol Head Neck Surg · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer. PMID 40850317 · Eur J Cancer · 2025-Oct-01 The record describes a randomized trial of a non-drug supportive care intervention (patient navigation with symptom monitoring) for advanced lung cancer. While it reports time-to-event endpoints (PFS, OS) as secondary outcomes, it does not meet the core criteria: (1) the trial phase is not specified as Phase III/IIIb or Phase II/III (sample size of 150 suggests an earlier phase), and (2) the intervention is not a drug-containing intervention. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer: Secondary Analysis of the Breast Cancer Weight Loss (BWEL) Trial. PMID 40839373 · JAMA Oncol · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants. PMID 40833801 · Pediatr Infect Dis J · 2025-Oct-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A novel approach to assess the prognostic value of toxicity profiles in gastric cancer patients undergoing preoperative treatment. PMID 40818318 · Eur J Cancer · 2025-Oct-01 The record describes a secondary/prognostic analysis of a randomized trial (CRITICS), not the primary or definitive efficacy report. The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III. While oncology, human, randomized, drug intervention, and time-to-event endpoints are present, the study is not an original primary result of a definitive-phase trial comparing interventions for efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial. PMID 40810951 · JAMA Oncol · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis. PMID 40810932 · JAMA Oncol · 2025-Oct-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Bacterial Decolonization With Mupirocin Ointment for Acute Radiation Oral Mucositis Prevention: A Phase 3 Randomized Clinical Trial. PMID 40773220 · JAMA Oncol · 2025-Oct-01 The study is an eligible Phase 3 randomized oncology trial with a drug intervention and original primary results, but it does not report a primary or key secondary time-to-event efficacy endpoint. The primary endpoint is the incidence of severe acute radiation oral mucositis (grade ≥3 AROM), which is a categorical toxicity/outcome measure, not a time-to-event measure like OS, PFS, DFS, etc. There is no mention of Kaplan-Meier analysis or hazard ratio. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial. PMID 40758358 · JAMA Intern Med · 2025-Oct-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial. PMID 40736443 · Clin Cancer Res · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders. PMID 40705465 · J Clin Invest · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Group-based trajectories of health-related quality of life among pediatric patients with high-risk Hodgkin lymphoma. PMID 40700618 · J Natl Cancer Inst · 2025-Oct-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | confirmed 1 Figure · 2 Panel · risk visible |
| Nodal Downstaging in Patients With Rectal Cancer: Survival Is Promising if YpN0 Is Achieved. PMID 40626521 · Dis Colon Rectum · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma. PMID 40579995 · Neuro Oncol · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term outcomes of single-incision laparoscopic surgery for colorectal cancer, a single-center, open-label, randomized controlled trial. PMID 40549445 · Int J Surg · 2025-Oct-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial. PMID 40490846 · Int J Cancer · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets. PMID 40489668 · Rheumatology (Oxford) · 2025-Oct-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |